These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27125751)

  • 1. Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer.
    Bikov KA; Mullins CD; Hung A; Seal B; Onukwugha E; Hanna N
    Oncologist; 2016 Jun; 21(6):676-83. PubMed ID: 27125751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients.
    Zheng Z; Hanna N; Onukwugha E; Reese ES; Seal B; Mullins CD
    Cancer Med; 2014 Feb; 3(1):124-33. PubMed ID: 24403130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
    Raab GT; Lin A; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Buono DL; Hur C; Kiran RP; Wright JD; Hershman DL; Neugut AI
    Clin Colorectal Cancer; 2019 Sep; 18(3):e294-e299. PubMed ID: 31266707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients.
    Reese ES; Onukwugha E; Hanna N; Seal BS; Mullins CD
    Cancer Med; 2013 Dec; 2(6):907-15. PubMed ID: 24403264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patients.
    Zheng Z; Onukwugha E; Hanna N; Bikov K; Seal B; Mullins CD
    Adv Ther; 2014 Jul; 31(7):724-34. PubMed ID: 25022528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients.
    Parikh RC; Du XL; Robert MO; Lairson DR
    J Manag Care Spec Pharm; 2017 Jan; 23(1):64-73. PubMed ID: 28025930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer.
    Seal BS; Anderson S; Shermock KM
    J Manag Care Spec Pharm; 2016 Mar; 22(3):227-35. PubMed ID: 27003552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Biologic Agents Among Black and White Medicare Patients in the US With Metastatic Colorectal Cancer.
    Goel S; Negassa A; Acuna-Villaorduna A
    JAMA Netw Open; 2021 Dec; 4(12):e2136378. PubMed ID: 34910154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unsupported off-label chemotherapy in metastatic colon cancer.
    de Souza JA; Polite B; Perkins M; Meropol NJ; Ratain MJ; Newcomer LN; Alexander GC
    BMC Health Serv Res; 2012 Dec; 12():481. PubMed ID: 23272659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review.
    Koilakou S; Petrou P
    Mol Diagn Ther; 2021 Nov; 25(6):715-734. PubMed ID: 34816395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary tumor location is an important predictive factor for wild-type KRAS metastatic colon cancer treated with cetuximab as front-line bio-therapy.
    Lu HJ; Lin JK; Chen WS; Jiang JK; Yang SH; Lan YT; Lin CC; Chang SC; Teng HW
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):207-15. PubMed ID: 26935130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Algorithm for identifying chemotherapy/biological regimens for metastatic colon cancer in SEER-Medicare.
    Bikov KA; Mullins CD; Seal B; Onukwugha E; Hanna N
    Med Care; 2015 Aug; 53(8):e58-64. PubMed ID: 23552436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
    Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
    Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?
    Semira C; Wong HL; Field K; Lee M; Lee B; Nott L; Shapiro J; Wong R; Tie J; Tran B; Richardson G; Zimet A; Lipton L; Tamjid B; Burge M; Ma B; Johns J; Harold M; Gibbs P
    Intern Med J; 2019 Apr; 49(4):446-454. PubMed ID: 30230679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
    Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
    Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Watanabe J; Muro K; Shitara K; Yamazaki K; Shiozawa M; Ohori H; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Hihara M; Soeda J; Misumi T; Yamamoto K; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
    JAMA; 2023 Apr; 329(15):1271-1282. PubMed ID: 37071094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer].
    Chen G
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jan; 20(1):28-33. PubMed ID: 28105616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
    Degirmencioglu S; Tanriverdi O; Menekse S; Dogan M; Hacıoglu B; Oktay E; Erdem D; Arpaci E; Uluc BO; Turhal S; Yilmaz M; Pilanci KN; Sakin A; Araz M; Cokmert S; Ozdemir O; Sen E; Nayir E
    J BUON; 2019; 24(1):136-142. PubMed ID: 30941962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.